- Home
- ITRM vs MNDO Comparison
ITRM vs MNDO Comparison
Compare ITRM & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- MNDO
- Stock Information
- Founded
- ITRM 2015
- MNDO 1995
- Country
- ITRM Ireland
- MNDO Israel
- Employees
- ITRM N/A
- MNDO N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- MNDO EDP Services
- Sector
- ITRM Health Care
- MNDO Technology
- Exchange
- ITRM Nasdaq
- MNDO Nasdaq
- Market Cap
- ITRM 40.0M
- MNDO 34.2M
- IPO Year
- ITRM 2018
- MNDO 2000
- Fundamental
- Price
- ITRM $1.01
- MNDO $1.32
- Analyst Decision
- ITRM Strong Buy
- MNDO
- Analyst Count
- ITRM 2
- MNDO 0
- Target Price
- ITRM $7.00
- MNDO N/A
- AVG Volume (30 Days)
- ITRM 481.0K
- MNDO 39.9K
- Earning Date
- ITRM 08-13-2025
- MNDO 08-05-2025
- Dividend Yield
- ITRM N/A
- MNDO 16.60%
- EPS Growth
- ITRM N/A
- MNDO N/A
- EPS
- ITRM N/A
- MNDO 0.17
- Revenue
- ITRM N/A
- MNDO $20,677,000.00
- Revenue This Year
- ITRM N/A
- MNDO N/A
- Revenue Next Year
- ITRM $270.19
- MNDO N/A
- P/E Ratio
- ITRM N/A
- MNDO $7.76
- Revenue Growth
- ITRM N/A
- MNDO N/A
- 52 Week Low
- ITRM $0.81
- MNDO $1.31
- 52 Week High
- ITRM $3.02
- MNDO $2.13
- Technical
- Relative Strength Index (RSI)
- ITRM 51.14
- MNDO 28.21
- Support Level
- ITRM $0.93
- MNDO $1.33
- Resistance Level
- ITRM $1.06
- MNDO $1.37
- Average True Range (ATR)
- ITRM 0.05
- MNDO 0.03
- MACD
- ITRM 0.01
- MNDO -0.01
- Stochastic Oscillator
- ITRM 34.78
- MNDO 5.26
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About MNDO MIND C.T.I. Ltd.
MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.